Dermira (NASDAQ:DERM) Rating Maintained
New York: In analysts report released on Tuesday morning, Mizuho Securities reconfirmed their “Buy” rating on shares of Dermira (NASDAQ:DERM). They currently have a $39.0 price target on the firm. Mizuho Securities’s target gives a potential upside of 45.69 % from the company’s close price.
Out of 5 analysts covering Dermira, 0 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $47 and the lowest is $40 according to Thomson/First Call. The 12-month mean target is $42.6, which means upside potential of 72.05% over the current price.
Great Point Partners Llc had the most significant stake with ownership of 679,403 shares as of q2 2015 for 5.86% of the US long Equity Exposure. Ecor1 Capital Llc is another quite bullish investment professional who is having 522,000 shares of Dermira or 5.42% of their US long equity exposure. Moreover, Nea Management Company Llc have 5.35% of their US long equity exposure invested in the company for 3.51 million shares. The California-based fund Blue Jay Capital Management Llc disclosed it had purchased so far a stake worth about 5.08% of the investment professional’s stock portfolio in Dermira. The California-based fund Venbio Select Advisor Llc is also positive about the stock, possessing 275,000 shares or 4.78% of their US long equity exposure.
Dermira (NASDAQ:DERM) Profile
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Dermira (NASDAQ:DERM) traded up 2.27% on 12 December, hitting $24.76. A total of 493,477 shares of the company’s stock traded hands. This is down from average of 561,077 shares. Dermira has a 52 week low of $21.35 and a 52 week high of $38.75. The company has a market cap of $1.03B and a P/E ratio of 0.
Get the latest Dermira (NASDAQ:DERM) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post New York: Dermira (NASDAQ:DERM)’s Stock Had Its “Buy” Rating Restated at Mizuho Securities in Report Issued Today. Has $39.0 Target appeared first on Octafinance.